Searched for
RESPIRATORY THERAPY SEGMENT
Lupin launches fixed-dose triple combination inhaler for COPD in IndiaLupin Ltd has launched Formoflo-G MDI, a new inhaler for chronic obstructive pulmonary disease management in India. This fixed-dose inhaler...- Short-term headwind? Yes. But the structure stays intact: 5 large-cap stocks with upside potential of up to 19%Wise men on the street will tell you it is foolish to try and time the market. And attempting to do so in the midst of a raging war is prob...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipelineIndian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...
- Indian pharma market's double-digit growth momentum is likely to continue further: EquirusThe Indian Pharmaceutical Market is set for continued double-digit growth. May's performance showed strong demand across all therapies. Chr...
- Cardiac drugs log highest sales in 2025 as NCD cases surgeHeart medicines led sales in 2025, a trend set to continue. Respiratory and anti-diabetes drugs followed. Cardiac drug sales grew 13%, with...
- Respiratory drug sales peak in November amid worsening AQIIndia's air quality decline is boosting medicines for breathing problems. The respiratory drug market grew 8% last month, a rise from previ...
- Cipla plans 4 major respiratory launches by 2026 after beating Q2 estimates with highest-ever quarterly revenue of Rs 7,500+ crCipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growin...
- High pollution may boost demand for respiratory drugs"The respiratory market shows the normal seasonal trend for the anti-asthma and cough and cold segment," said Sheetal Sapale, VP, commercia...
- As monsoon takes hold, anti-infective, respiratory drugs' demand surgesMonsoon led to a surge in demand for respiratory, anti-infective, and anti-malarial products. The respiratory market saw a notable increase...
- Domestic pharma market growth slips to 6% in JulySheetal Sapale, VP, commercial, Pharmarack, said four key therapy segments - cardiac, anti-infectives, gastro and respiratory - have driven...
- Pharma market grows 9% in Feb on price increase, new productsIndia's pharmaceutical market witnessed a robust 9% month-on-month growth in February, driven by strong performance in cardiology and anti-...
- Pharma growth shrinks to 4.5% in June as Covid-led segments show decrease in salesIndia's pharmaceutical market contracted by 4.5% in June due to a fall in anti-infectives and respiratory drug sales as Covid cases decreas...
- India's pharma market grows 8% in '22 led by price hikesIn 2021, the market had shown a growth of 14.9%, primarily because of a low base, and the high volume offtake of Covid-19 and related medic...
- Cipla to invest 15 million euros in Germany’s Ethris to expand respiratory portfolioThe investment will facilitate a long-term strategic partnership between Cipla and Ethris for development of messenger RNA (mRNA)-based the...
- Lupin inks pact to acquire two inhalation brands from Sunovion for USD 75 mnThe acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the res...
- Sun Pharma-Ranbaxy combine creates a new market leader in Indian marketThe proposed new entity would unseat Abbott from the top position, which holds current market share of 6.5%, according to research firm Aio...
- Domestic Pharma Growth Improves for the month of MaySequentially, the domestic pharma industry staged an improvement for the month of May. At 9.9%, according to data compiled by PharmaTrac
- Lupin eyes two marketing alliances by MarchApart from vaccines, Lupin is also scouting for a partner to help market cardiovascular, diabetes, gynecology and respiratory drugs.
Load More
